06 September, 2017
Alliancebernstein L.P. lifted its holdings in shares of Clovis Oncology by 1,538.0% in the 1st quarter.
The recently concluded session had traders exchanging MagneGas Corporation (NASDAQ:MNGA) low level. The institutional investor owned 29,330 shares of the biopharmaceutical company's stock after buying an additional 6,265 shares during the quarter. The stock of Clovis Oncology Inc (NASDAQ:CLVS) has "Neutral" rating given on Monday, November 16 by Mizuho.
Blue Jay Capital Management Llc decreased Clovis Oncology Inc (CLVS) stake by 10.75% reported in 2016Q4 SEC filing. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Clovis Oncology by 71.4% during the first quarter.
The counter witnessed a trading volume of 1.37 million shares versus an average volume of 1.93 million shares during last trading session. Tower Cap Lc (Trc) has invested 0% in Lakeland Industries, Inc. Return on assets ratio of the Company was -68.90%. Blackrock Institutional Trust Communication Na holds 0.01% in Clovis Oncology Inc (NASDAQ:CLVS) or 912,651 shares. The Bourgeon Capital Management Llc holds 5,250 shares with $233,000 value, down from 14,850 last quarter. Finally, Quantbot Technologies LP bought a new position in Clovis Oncology during the first quarter valued at about $185,000.
Several research firms have weighed in on CLVS. Columbia Wanger Asset Mngmt Limited Liability holds 0.12% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS) for 189,958 shares.
FT reports, The 11 analysts offering 12 month price targets for Clovis Oncology Inc have a median target of 97.00, with a high estimate of 125.00 and a low estimate of 49.00. RBC Capital Markets maintained the shares of JNJ in report on Sunday, August 27 with "Buy" rating. Cann began coverage on Clovis Oncology in a research note on Thursday, June 22nd. Also, the current price highlights a discount of 59.72% to analysts' high consensus price target. They issued an "outperform" rating and a $85.00 price objective for the company. If it moves beyond 70 but cannot hold this ground and instead falls below 70, it could be an indication that the market is overbought and prone to become bearish, at least in the short term. The company now has a consensus rating of "Buy" and an average price target of $85.16.
This stock (MNGA) is ahead of its 52-week low with 45%. (CLVS) opened at 76.65 on Wednesday.
The short ratio in the company's stock is documented at 3.89 and the short float is around of 15.88%. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.27) by $0.02. The business had revenue of $14.62 million for the quarter, compared to analysts' expectations of $13.07 million.
How Active Are Clovis Oncology, Inc. During the same period in the previous year, the firm earned ($2.07) EPS. Clovis Oncology Inc now has $3.83 billion valuation. Blue Jay Limited Liability Corp has 8.01% invested in Clovis Oncology Inc (NASDAQ:CLVS). "(CLVS)" was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this report on another site, it was illegally stolen and republished in violation of global copyright laws. About shares traded. Clovis Oncology Inc (NASDAQ:CLVS) has risen 282.71% since September 5, 2016 and is uptrending. On the flip side, if the indicator goes under -80, this may signal that the stock is oversold. Moving averages are considered to be lagging indicators that simply take the average price of a stock over a certain period of time. Following the completion of the sale, the insider now directly owns 194,583 shares of the company's stock, valued at approximately $13,630,539.15.
In related news, Director James C. Blair sold 18,450 shares of Clovis Oncology stock in a transaction dated Friday, August 4th. The stock increased 2.88% or $2.19 on September 1, reaching $78.26. Following the completion of the transaction, the director now owns 2,185 shares in the company, valued at $171,762.85. The disclosure for this sale can be found here. Insiders own 17.40% of the company's stock.
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other global markets. The Company's product candidates include Rociletinib, Rubraca and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the fix of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
A number of other hedge funds have also modified their holdings of CLVS.
